STD cases on the rise, what you need to know about melioidosis

0

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Despite a pandemic-induced decrease in STDs in the United States, cases have resurfaced. The CDC reported that cases of gonorrhea and syphilis by the end of 2020 were up 7% and 1%, respectively, from 2019.

A data report was the main story of infectious diseases last week.

Source: Pagoa M, et al. Trans Sex Dis. 2021; doi: 10.1097 / OLQ.0000000000001506.

Another Featured Story featured an interview with Jill Meteor, MD, MS, DTMandH, FAAP, on the CDC’s melioidosis alert and what clinicians need to know. Weatherhead said melioidosis can often be confused with pulmonary tuberculosis.

Read these and other articles on infectious diseases below:

CDC data shows resurgence of STDs after pandemic decline

STDs reappeared in the United States by the end of 2020 following a drop in reported cases of chlamydia, gonorrhea and syphilis in March and April during the first peak of COVID-19, according to a new report . Read more.

Q&A: CDC alerts U.S. clinicians of non-travel cases of melioidosis

The CDC recently issued a health advisory regarding three cases of melioidosis in the United States that appear unrelated to travel. Read more.

Could Delta change the trajectory of COVID-19 in the United States?

After weeks of declining cases followed by a plateau, the United States is once again seeing an increase in COVID-19 in many parts of the country, a CDC official warned this week. Read more.

Exposure to common non-antimicrobial drugs can lead to drug-resistant infections

Exposure to commonly prescribed non-antimicrobial drugs was associated with an increased risk of drug-resistant infections in a study of more than 1,800 patients in an Israeli hospital, researchers reported at the virtual meeting of the ECCMID. Read more.

Antibody cocktail reduces risk of death and hospitalization for COVID-19

Bamlanivimab plus etesevimab (Eli Lilly) monoclonal antibody cocktail reduced risk of COVID-19-related death and hospitalization in high-risk outpatients compared to placebo, phase trial results show 3. Read more.


Source link

Leave A Reply

Your email address will not be published.